Courtney E King1, Howard C Becker2,3. 1. Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Department of Neuroscience, Medical University of South Carolina, 67 President Street, MSC-861, Charleston, SC, 29425, USA. 2. Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Department of Neuroscience, Medical University of South Carolina, 67 President Street, MSC-861, Charleston, SC, 29425, USA. beckerh@musc.edu. 3. RHJ Department of Veterans Affairs Medical Center, Charleston, SC, 29425, USA. beckerh@musc.edu.
Abstract
RATIONALE: The neuropeptide oxytocin (OXT) has emerged as a potential therapeutic intervention in the treatment of both alcohol use disorder (AUD) and stress-related psychiatric illnesses. OBJECTIVES: The present study evaluates the effects of systemically administered (intraperitoneal (i.p.)) OXT treatment on alcohol relapse-like behavior in male and female mice. METHODS: Adult male and female C57BL/6J mice were trained to lever respond in operant conditioning chambers for alcohol in daily self-administration sessions. Once lever responding and alcohol intake stabilized, mice were tested under extinction conditions for 14 days before reinstatement testing. All mice underwent stress-induced reinstatement testing using either predator odor (2,3,5-trimethyl-3-thiazoline (TMT)) or the α-2 adrenergic receptor agonist yohimbine. In study 1, mice were exposed to TMT for 15 min and then immediately placed into operant conditioning chambers to examine alcohol-seeking behavior under extinction conditions. At 30 min prior to test session, separate groups of mice were injected with vehicle or OXT (0.1, 0.5, 1 mg/kg). In study 2, mice were injected with yohimbine (0.3, 0.625 mg/kg) 1 h prior to reinstatement testing. At 30 min post-yohimbine injection, mice are injected (i.p.) with vehicle or OXT (1 mg/kg). RESULTS: OXT attenuated alcohol-seeking behavior in a dose-related manner in male and female mice in response to acute challenge with a predator odor. Additionally, OXT administration produced a similar decrease in alcohol relapse-like behavior triggered by the pharmacological stressor yohimbine in both sexes. CONCLUSIONS: Systemic oxytocin administration attenuates stress-induced reinstatement of alcohol seeking in male and female mice.
RATIONALE: The neuropeptide oxytocin (OXT) has emerged as a potential therapeutic intervention in the treatment of both alcohol use disorder (AUD) and stress-related psychiatric illnesses. OBJECTIVES: The present study evaluates the effects of systemically administered (intraperitoneal (i.p.)) OXT treatment on alcohol relapse-like behavior in male and female mice. METHODS: Adult male and female C57BL/6J mice were trained to lever respond in operant conditioning chambers for alcohol in daily self-administration sessions. Once lever responding and alcohol intake stabilized, mice were tested under extinction conditions for 14 days before reinstatement testing. All mice underwent stress-induced reinstatement testing using either predator odor (2,3,5-trimethyl-3-thiazoline (TMT)) or the α-2 adrenergic receptor agonist yohimbine. In study 1, mice were exposed to TMT for 15 min and then immediately placed into operant conditioning chambers to examine alcohol-seeking behavior under extinction conditions. At 30 min prior to test session, separate groups of mice were injected with vehicle or OXT (0.1, 0.5, 1 mg/kg). In study 2, mice were injected with yohimbine (0.3, 0.625 mg/kg) 1 h prior to reinstatement testing. At 30 min post-yohimbine injection, mice are injected (i.p.) with vehicle or OXT (1 mg/kg). RESULTS:OXT attenuated alcohol-seeking behavior in a dose-related manner in male and female mice in response to acute challenge with a predator odor. Additionally, OXT administration produced a similar decrease in alcohol relapse-like behavior triggered by the pharmacological stressor yohimbine in both sexes. CONCLUSIONS: Systemic oxytocin administration attenuates stress-induced reinstatement of alcohol seeking in male and female mice.
Authors: Yann S Mineur; Vernon Garcia-Rivas; Merrilee A Thomas; Alexa R Soares; Sherry A McKee; Marina R Picciotto Journal: Psychopharmacology (Berl) Date: 2022-03-31 Impact factor: 4.530
Authors: Julianne C Flanagan; Paul J Nietert; Lauren Sippel; Amber M Jarnecke; Charli Kirby; Jasara N Hogan; Andrea A Massa; Jessica Brower; Sudie E Back; Dominic Parrott Journal: J Psychiatr Res Date: 2022-06-09 Impact factor: 5.250
Authors: Reginald Cannady; Tiffany Nguyen; Audrey E Padula; Jennifer A Rinker; Marcelo F Lopez; Howard C Becker; John J Woodward; Patrick J Mulholland Journal: Neuropharmacology Date: 2020-11-09 Impact factor: 5.250
Authors: Laura C Ornelas; Ryan E Tyler; Preethi Irukulapati; Sudheesha Paladugu; Joyce Besheer Journal: Behav Brain Res Date: 2020-12-14 Impact factor: 3.332